Floatz logo

e-602

Bladder Cancer

Palleon Pharmaceuticals, Inc.Phase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

121 Active assets in the Bladder Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
VINBLASTINE
University of Southern California
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

e-602 is also rated in:

gastroesophageal junction adenocarcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →